Monteris Medical Inc., a privately held medical device company dedicated to the development of innovative MRI guided, laser-based cancer treatments announced today it has secured $9 million in financing to support the continued commercialization of the company's NeuroBlate™ System (formerly AutoLITT®) within the North American neurosurgery market.
“SWMF was created to support very early stage companies on their path towards commercialization”
Business Development Bank of Canada (BDC) led the round. Other investors included the SWMF Life Science Fund, a group assembled by Richardson GMP and a number of independent parties.
John E. Schellhorn, President & Chief Executive Officer of Monteris remarks, "We are extremely grateful for the funding and support we have received from BDC, SWMF Life Science Fund, and Richardson GMP. "The timing is right for Monteris to complete development of our new technology platforms, to continue expansion throughout the U.S. Schellhorn concluded, "Our NeuroBlate™ System offers neurosurgeons another controlled therapy for difficult-to-treat brain tumors. We are committed to helping them offer critically ill patients hope in the form of MRI guided neurosurgical ablation."
"Monteris Medical is clearly representative of the dynamic, leading-edge technology companies in which BDC invests. We are pleased to have led this round of financing," states Gary Bantle, Partner, Health Venture Fund. "This venture capital investment represents our continued commitment to the Manitoba market and is evidence that good quality opportunities for growth in this sector are still available,"
"The SWMF Life Science Fund has been involved with Monteris since 2008," added Managing Director, Pat Morand. "SWMF was created to support very early stage companies on their path towards commercialization, "It is very satisfying to see how an early stage company can progress when given the resources to do so."
Breakthrough imaging method enhances precision in prostate cancer treatment